Who Paid My Doc
John Blankenship
Athens, GA Medical Doctor
NPI 1730160177 CMS profile 169867
1500 Oglethorpe Ave, Suite 2000, Athens, GA 30606
General payments
$9,206
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, John Blankenship of Athens, GA is reported in the CMS Open Payments database as having received $9,206 across 392 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,316 | 42 | |
| 2024 | General | $2,070 | 71 | |
| 2023 | General | $1,533 | 60 | |
| 2022 | General | $1,421 | 62 | |
| 2021 | General | $1,272 | 58 | |
| 2020 | General | $630 | 39 | |
| 2019 | General | $965 | 60 |
Beside peers
- John Blankenship
- Georgia median
- Middle half of Georgia
- National median
In program year 2025, general payments to John Blankenship were reported at $1,316. Among 34,129 Georgia profiles paid that year, the median was $183 and the middle half received between $50 and $656.
Show as a table
| Year | John Blankenship | Georgia median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $965 | $177 | $54–$648 | $163 |
| 2020 | $630 | $130 | $38–$432 | $114 |
| 2021 | $1,272 | $141 | $38–$499 | $132 |
| 2022 | $1,421 | $164 | $45–$574 | $149 |
| 2023 | $1,533 | $177 | $49–$620 | $160 |
| 2024 | $2,070 | $177 | $51–$638 | $164 |
| 2025 | $1,316 | $183 | $50–$656 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 51 drugsPart D claims
6,903
Drug cost
$2,464,454
Branded share of claims
42.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Xtandi Enzalutamide | Brand | 108 | $1,562,297 | |
| Orgovyx Relugolix | Brand | 107 | $288,626 | |
| Myrbetriq Mirabegron | Brand | 354 | $243,604 | |
| Nubeqa Darolutamide | Brand | 12 | $161,438 | |
| Gemtesa Vibegron | Brand | 87 | $58,492 | |
| Alfuzosin Hcl Er Alfuzosin Hcl | Brand | 677 | $15,906 | |
| Testosterone | Generic | 77 | $15,464 | |
| Tamsulosin Hcl | Generic | 943 | $13,900 | |
| Estradiol | Generic | 177 | $11,823 | |
| Elmiron Pentosan Polysulfate Sodium | Brand | 11 | $10,846 |
The 10 drugs with the highest cost, of 51 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 146 billing codesPaid by Medicare
$909,485
Medicare patients
1,558
Services billed
30,401
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 49% | |
| Ischemic heart disease | 35% | |
| Chronic kidney disease | 34% | |
| Diabetes | 31% | |
| Cancer | 28% | |
| Atrial fibrillation | 21% | |
| Heart failure | 20% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, onabotulinumtoxina, 1 unit J0585 | Office | 23 | 4,500 | $22,428 |
| Leuprolide acetate (for depot suspension), 7.5 mg J9217 | Office | 24 | 165 | $22,039 |
| Injection, fentanyl citrate, 0.1 mg J3010 | Office | 205 | 345 | $237 |
| Injection, ceftriaxone sodium, per 250 mg J0696 | Office | 97 | 422 | $146 |
| Injection, propofol, 10 mg J2704 | Office | 48 | 1,141 | $103 |
| Injection, midazolam hydrochloride, per 1 mg J2250 | Office | 221 | 767 | $79 |
| Injection, garamycin, gentamicin, up to 80 mg J1580 | Office | 15 | 22 | $36 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 18 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| ADSTILADRIN |
|
$278 | — | — |
| BOTOX |
|
$210 | — | 4,500 |
| Nubeqa |
|
$167 | 12 | — |
| ORGOVYX |
|
$163 | 107 | — |
| ERLEADA |
|
$136 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 18 in the dashboard with a free accountRecords
392 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.